Țară: Canada
Limbă: engleză
Sursă: Health Canada
ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE)
DOMINION PHARMACAL
L01XX35
ANAGRELIDE
0.5MG
CAPSULE
ANAGRELIDE (ANAGRELIDE HYDROCHLORIDE MONOHYDRATE) 0.5MG
ORAL
100
Prescription
PLATELET-REDUCING AGENTS
Active ingredient group (AIG) number: 0131875001; AHFS:
APPROVED
2006-06-16
PRODUCT MONOGRAPH PR DOM-ANAGRELIDE Anagrelide Capsules, House Standard 0.5 mg PLATELET-REDUCING AGENT DOMINION PHARMACAL 6111 Royalmount Avenue, Suite #100 Montréal, Québec H4P 2T4 DATE OF REVISION: May 18, 2017 SUBMISSION CONTROL NO.: 205385 _ _ _Dom-ANAGRELIDE Product Monograph _ _Page 2 of 32_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................................................... 3 CONTRAINDICATIONS ............................................................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................................................. 4 ADVERSE REACTIONS ................................................................................................................................ 7 DRUG INTERACTIONS .............................................................................................................................. 10 DOSAGE AND ADMINISTRATION .......................................................................................................... 12 OVERDOSAGE ............................................................................................................................................ 13 ACTION AND CLINICAL PHARMACOLOGY ......................................................................................... 13 STORAGE AND STABILITY ...................................................................................................................... 17 DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................................................... 17 PART II: SCIENTIFIC INFORMATION ................................. Citiți documentul complet